3 Obscure Small-Cap Stocks Nobody Is Watching Right Now

Everyone and their broker is glued to Mag-7 earnings right now. Fair enough. But while the financial internet collectively screams about Google's negative free cash flow and Tesla's 14% face-plant, a different kind of opportunity quietly exists in the parts of the market where analysts rarely bother to open a spreadsheet.

Here are three small-cap and mid-cap names catching attention in our sentiment data, each with a specific catalyst that could actually move the stock.

$CORT (Corcept Therapeutics) is a Menlo Park-based pharmaceutical company that has built a surprisingly durable franchise around cortisol modulation. Their lead drug, mifepristone under the brand name Korlym, treats Cushing's syndrome, a rare endocrine disorder affecting fewer than 100,000 Americans. What makes Corcept interesting right now is a pipeline of next-generation compounds targeting solid tumors using the same cortisol-blocking mechanism. The company has a market cap well under $5 billion, generates real cash flow (rare in biotech), and carries almost no debt. It flies under the radar because it lacks the AI buzzword and the flashy investor day PowerPoints. The catalyst: Phase 3 data for relacorilant in metastatic pancreatic cancer is expected in late 2026. A positive readout would absolutely reprice this stock.

$RLAY (Relay Therapeutics) is a Cambridge-based precision oncology company using a computational protein motion platform it calls Dynamo to identify drug targets that static structure tools miss entirely. The market cap sits around $600 million, which for a clinical-stage biotech with real platform differentiation is genuinely small. Relay's lead program RLY-2608, targeting PI3K-alpha mutations in breast cancer, showed durable responses in patients who had already failed standard-of-care. The bears will correctly point out it burns cash and has no approved products. The bulls will note that if RLY-2608 produces strong Phase 2 data expected in the second half of 2026, this name becomes an acquisition target almost overnight. Every large pharma company is hunting differentiated oncology assets right now, especially with Sanofi just blowing up a $5 billion eczema program.

$IIPR (Innovative Industrial Properties) is the rare cannabis-adjacent REIT that actually makes money. The company acquires and leases specialized industrial real estate to regulated cannabis operators across the US, collecting rent the way any landlord does, except with yields that make most REITs look pedestrian. IIPR currently yields north of 7%, has raised its dividend consistently, and trades at a meaningful discount to net asset value. It is under the radar because institutional investors are still skittish about anything touching cannabis even when the underlying business is pure real estate. The catalyst here is federal rescheduling of cannabis from Schedule I to Schedule III, which would unlock banking access for tenants and dramatically reduce credit risk across IIPR's portfolio. That process is still grinding through regulatory review.

Three completely different sectors, three completely different risk profiles. The one thing they share is that almost nobody on financial Twitter is talking about them today, which historically tends to be exactly the right time to start paying attention.